Chemoradiation is considered a reasonable treatment option for patients with locally advanced, unresectable pancreatic cancer. The chemotherapy agents 5-fluorouracil, gemcitabine, capecitabine and ...

Toxicology and clinical protocol development of DUO-207: An ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel for the treatment of metastatic pancreatic cancer. This is an ASCO Meeting ...

If it’s unresectable, you need therapy that goes everywhere in the body and that is generally chemotherapy.” Symptoms of ...

Disparities in outcomes of pancreatic cancer hospitalizations: A ten-year trend study. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

Historically, high-dose radiation has been considered beneficial for improving survival rates in patients with unresectable pancreatic cancer. Yet, the application has often been limited due to ...

The Gastrointestinal Tumor Study Group study and the Mayo Clinic study helped define chemoradiation with 5FU as the standard of care in locally advanced pancreatic cancer. Currently, typical ...

perform a phase II trial of atezolizumab monotherapy following platinum-based definitive chemoradiotherapy in patients with unresectable ... patients with pancreatic ductal adenocarcinoma who ...

The San Francisco biotech confirmed that neither the PanCAN Precision Promise study in metastatic pancreatic cancer nor the LAPIS trial in patients with locally advanced, unresectable pancreatic ...

Opens in a new tab or window SAN FRANCISCO -- Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after treatment with a ...

Under the name apatinib (Aitan), rivoceranib was approved in gastric cancer in China in 2014; it was approved in combination with camrelizumab as first-line treatment for unresectable HCC in 2023.